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Abstract
The main aim of this work was to develop novel targeted sterically stabilised pH-sensitive liposomes tailored to promote efficient
intracellular delivery of therapeutic molecules into human T-leukaemia cells. Our results indicate that the targeting moiety (thiolated
transferrin) was successfully coupled to the distal reactive maleimide terminus of poly(ethylene glycol)–phospholipid conjugates
incorporated in the liposomal bilayer. Results from atomic force microscopy studies, performed to characterise vesicle surface topology,
indicated that, to a certain extent, thiolated transferrin has the ability to associate in a non-specific manner with the lipid membrane of
pegylated liposomes. This is an issue not commonly reported in the literature but which is crucial to demonstrate the targeting proof of
principle. Nevertheless, fluorimetric studies together with confocal microscopy clearly demonstrate that liposomes bearing covalently
coupled transferrin associate more extensively to human T-leukaemia cells in vitro than non-targeted liposomes. Cell mechanistic studies
indicate that targeted liposomes bind specifically to transferrin receptors and are internalised via receptor-dependent endocytotic pathway.
In addition, the biophysical features exhibited by the developed liposomes, namely their ability to promote pH-triggered cytoplasmic
delivery of loaded material, make them promising delivery systems for in vivo targeting of therapeutic molecules to tumours.
q 2004 Elsevier B.V. All rights reserved.
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The success of novel strategies for cancer therapy
strongly relies on the development of formulations capable
of improving the therapeutic index of biologically active
molecules, namely by increasing their concentration at
desired target sites while avoiding normal tissues. Among
other nanovesicular vectors currently under investigation,
liposomes (phospholipid bilayer vesicles) have attracted
considerable interest as site-specific delivery systems,
because of their biocompatibility and chemical and0939-6411/$ - see front matter q 2004 Elsevier B.V. All rights reserved.
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fate not only in vivo but also at an intracellular level [1,2].
Targeting to cancer cell surface antigens constitutes a
promising, although challenging approach that can be
applied to liposomes in order to promote specific drug
delivery into tumours [3]. In this context, covalent coupling
of antibodies or other ligands to the distal reactive end of
poly(ethylene glycol)–phospholipid conjugates incorpor-
ated in the liposomal bilayer has resulted in formulations
exhibiting both prolonged circulation half-lives in blood and
cell targeting specificity [4,5]. However, the clinical success
of such approaches depends on the selection of appropriate
ligands, lacking immunogenic potential and with the ability
to mediate cargo internalisation by the target cells [3].
Moreover, upon nanovesicle–cell interaction, it is still
desirable to ensure an efficient intracellular delivery ofEuropean Journal of Pharmaceutics and Biopharmaceutics 59 (2005) 359–366www.elsevier.com/locate/ejpb
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somes, that are stable at physiological pH but undergo
destabilisation and acquire fusogenic properties under
acidic conditions, thus leading to the release of their
aqueous contents, constitute a promising strategy [2,6]. The
concept of pH-sensitive liposomes emerged from the fact
that certain enveloped viruses developed strategies to take
advantage of the acidification of the endosomal lumen to
infect cells, and from the observation that some pathological
tissues (tumours, sites of inflammation and infected areas)
exhibit an acidic environment as compared to normal tissues
[6–8]. Different classes of pH-sensitive liposomes have
been described in the literature according to the mechanism
triggering pH-sensitivity [2,7,9]. In our laboratory, very
promising results have been obtained with sterically
stabilised liposomes composed of phosphatidylethanola-
mine (PE) (or its derivatives) with compounds containing an
acidic group (e.g. carboxylic group) that act as a stabiliser at
neutral pH [6,10]. This is a simple, non-expensive and easily
scaled-up formulation that avoids the use of pH-sensitive
peptides and polymers, which may be responsible for
immune responses and toxicity [6,9].
In this work, transferrin, a glycoprotein which transports
ferric ion into cells, was tested as a ligand to target sterically
stabilised pH-sensitive liposomes to human T-leukaemia
cells. Two main reasons dictated the choice of this ligand:
(i) the over-expression of its receptor on these cells, and (ii)
the ability of transferrin to promote receptor-mediated
endocytosis, which would enhance intracellular delivery of
the carried material [11]. In addition, transferrin is non-
immunogenic and can be conjugated without losing its
biological activity, which make this protein an interesting
and promising tumour-targeting ligand [12]. Surface
topology analysis of the developed targeted liposomes
indicated that currently used coupling procedures may lead
to non-specific adsorption of ligands to liposomes surface.
This is an issue not commonly reported in the literature but
which is crucial to demonstrate the targeting proof of
principle. However, cell association studies, performed in
the presence or absence of drugs that interfere with the
endocytotic pathway, demonstrated that targeted liposomes
bind specifically to cell surface Trf receptors and are
internalised via a receptor-dependent endocytic pathway.2. Materials and methods
2.1. Materials
Dioleoylphosphatidylethanolamine (DOPE), methoxy-
poly(ethylene glycol)-distearoylphosphatidylethanolamine
(Mw 2000) (mPEG2000-DSPE), maleimide-derivatised
poly(ethylene glycol)-distearoylphosphatidylethanolamine
((Mal)PEG2000-DSPE), and rodamine labelled-phosphati-
dylethanolamine (Rh-PE) were obtained from Avanti Polar
Lipids (Alabaster, AL). Cholesteroyl hemisuccinate(CHEMS), human holo-Transferrin (Trf), 2-iminothiolane,
bicinchoninic acid (BCA) protein kit, Sepharose CL-4B,
Sephadex G-25, N-(2-hydroxyethyl)piperazine-N 0-(2-etha-
nesulfonic acid) (HEPES) were purchased from Sigma
Chemical Co. (St Louis, MO).
2.2. Preparation of liposomes
Liposomes composed of DOPE:CHEMS:PEG2000-
DSPE:(Mal)PEG2000-DSPE (6:4:0.06:0.24, molar ratio) or
DOPE:CHEMS:PEG2000-DSPE (6:4:0.3, molar ratio) at a
DOPE concentration of 10 mM, were prepared by the
reverse phase method previously described by Szoka and
Papahadjopoulos [13]. When necessary, 5 mol% of Rh-PE
relative to DOPE concentration was also included in the
lipid bilayer. Briefly, a mixture of the appropriate amounts
of lipids from stock solutions in chloroform was dried in a
rotary evaporator under reduced pressure in order to obtain a
thin lipid film. The film was dissolved in 800 ml of pre-
washed diethyl ether, and 300 ml of HEPES buffer (75 mM
HEPES, 2 mM EDTA, 290 mOsm NaCl, pH 7.2) were then
added. This mixture was sonicated briefly to form a stable
emulsion. The ether was removed in a rotary evaporator
under controlled vacuum at 37 8C, to obtain a semi-solid gel.
An additional aliquot of 700 ml of HEPES buffer was added
to the gel, which was then broken by vigorous mechanical
shaking with a vortex mixer. Evaporation was continued to
remove any residual ether. Vesicles were extruded (21!)
through two polycarbonate membranes of 80 nm pore
diameter using a LipoFast mini extruder (Lipofast, Avestin,
Toronto, Canada) to obtain a uniform size distribution. Final
lipid concentrations were determined based on lipid
phosphorous assay by Fiske and Subarrow [14].
2.3. Preparation of thiolated transferrin and coupling
procedure
Transferrin and 2-iminothiolane were both dissolved in
HEPES buffer (25 mM HEPES, 140 mM NaCl, pH 8) and
mixed at a 1:10 molar ratio. This mixture was left to react
for 1 h, at room temperature, under dark conditions and
under an inert N2 atmosphere. Upon purification by gel
chromatography (Sephadex G-25 spin column), 50 ml of
thiolated-transferrin was immediately added to 400 ml of
freshly prepared liposomes (final phospholipid concen-
tration of 10 mM) at different Trf-SH:phospholipid molar
ratios as indicated in the legend to the Fig. 1. The resulting
suspension was left to react overnight at room temperature
under magnetic stirring, dark conditions and under an inert
N2 atmosphere. Free maleimide groups were quenched with
a 5-fold excess of 2-mercaptoethanol (50 ml of a 4 mM
solution) relative to (Mal)PEG-DSPE concentration in the
final reaction mixture, for 30 min at room temperature. Free
transferrin was separated from liposomes by size exclu-
sion chromatography using a Sepharose CL-4B column
equilibrated in 25 mM HEPES 140 mM NaCl, pH 7.4.
Fig. 1. Effect of the initial Trf-SH:phospholipid molar ratio on the amount
of Trf coupled to liposomes. Liposomes were prepared according to the
reverse phase evaporation procedure previously described by Szoka and
Papahadjopoulos [13]. Liposomes composed of a mixture of
DOPE:CHEMS:PEG2000-DSPE:(Mal)PEG2000-DSPE (6:4:0.24:0.06) or
DOPE:CHEMS:PEG2000-DSPE (6:4:0.3) at a DOPE concentration of
10 mM, were incubated with (A) various amounts of thiolated Trf at Trf-
SH:phospholipid molar ratios ranging from 1:1000 to 10:1000 or (B) with
thiolated or non-thiolated Trf at a Trf:phospholipid molar ratio of 10:1000.
In both cases (A and B), free transferrin was separated from liposomes by
size exclusion chromatography using a Sepharose CL-4B column
equilibrated in HEPES buffered saline solution (25 mM Hepes, 140 mM
NaCl, pH 7.4). The amount of protein coupled to liposomes was determined
by the bicinchoninic acid method (BCA).
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by the bicinchoninic acid method (BCA).2.4. Surface topography analysis
Surface topography analysis was performed by atomic
force microscopy (AFM). Liposomes were deposited on
freshly cleaved mica and incubated for 30 min in HEPES
buffer at pH 7.4 (0.5 mM final concentration of phospholi-
pid). The surface was then rinsed gently with HEPES buffer
at room temperature. Samples were kept in HEPES buffer
and introduced as such into the AFM fluid cell. All imaging
was performed using a Digital Instruments Nanoscope IIIa
AFM system (Santa Barbara, CA) and a tapping mode fluid
cell. Commercially available cantilever with Si3N4 tips were
used (Olympus Ltd, Tokyo, Japan). Heights of the images
were determined by cross-sectional analysis.2.5. Mean diameter and surface charge
Mean diameter and polydispersity index of the pre-
viously described formulations, were evaluated by photon
correlation spectroscopy (Coulter N4 Plus, Coulter Elec-
tronics, Hialeah, FL), upon the appropriate dilution of the
different liposome formulations in previously filtered
HEPES buffer at pH 7.4. Surface charge was determined
by Doppler Electrophoretic Light Scattering Analysis
(DELSA) using a Coulter DELSA 440 (Coulter Electronics,
Hialeah, FL). Samples were diluted in HEPES buffer and
placed in the measurement cell, whose position was
adjusted to cover a previously determined stationary layer
and an electric field of 3.0 mA was applied. Data were
recorded and the z potential calculated for each scattering
angle (8.6, 17.1, 25.6 and 34.28).
2.6. Cells
Two different human acute limphoblastic leukaemia cell
lines were used in this study: CEM and MOLT-3 (DSMZ,
Braunschweig, Germany). Cells were cultured in suspen-
sion in RPMI-1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Biochron, Berlin,
Germany) and antibiotics (100 mg/ml streptomycin and
100 unit/ml of penicillin) (Sigma, St Louis, MO) at 37 8C in
balanced air humidified incubator (90% humidity) under 5%
CO2. Cells were maintained in an exponential growth phase
by periodic dilutions in fresh medium.
2.7. Cell association studies
One million CEM or MOLT-3 cells were incubated for
30 min at 37 8C in RPMI medium in the absence (control) or
presence of an excess of free Trf (8 mg/well) or with
cytochalasin B (25 mg/ml). Cells were further incubated for
2 h at 37 8C with different liposome formulations (final
phospholipid concentration of 300 mM). Cells were then
analysed for their fluorescence content following the
addition of C12E8 at excitation and emission wavelengths
of 570 and 590 nm, respectively. The sample chamber was
adjusted to the front face configuration (to prevent light
scattering contributions to the fluorescence) and equipped
with a magnetic stirrer. The temperature was maintained at
20 8C with a termostated circulating water bath. Fluor-
escence measurements were performed in a SPEX Fluor-
olog 2 fluorimeter (SPEX Industries, Edison, NJ).
2.8. Confocal microscopy analysis
Cells (1!106/well) were seeded in 48 multi-wells plates
and incubated with Trf-SH-(Mal)PEG-Liposomes (tar-
geted-liposomes) or with (Mal)PEG-Liposomes (liposomes
without Trf) for 2 h at 37 8C (final phospholipid concen-
tration of 300 mM). In some experiments cells were pre-
treated for 30 min at 37 8C with inhibitors of endocytosis
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fluoride (10 mM)). After incubation, cells were washed
twice with cold PBS, fixed with 4% solution of parafor-
maldehyde in PBS for 15 min and washed twice again with
cold PBS. Cells were then observed under a confocal
microscope (Bio-Rad, MRC 600, Hercules, CA).3. Results and discussion
Different methodologies have been described to cova-
lently attach ligands to the reactive distal end of PEG
molecules [15,16]. In this work covalent coupling
of thiolated transferrin to the maleimide terminus of
distearoylphosphatidylethanolamine–poly(ethylene) glycol
(DSPE-PEG) molecules ((Mal)PEG-DSPE) was explored
[12]. This methodology was chosen because the reaction
between thiol and maleimide groups was reported as one of
the most efficient reactions in bioconjugate chemistry
resulting in a stable thio-ether linkage; it occurs at room
temperature and at pH close to neutrality [17,18]. The latter
aspect is a crucial issue in this study since the liposomes
exhibit pH-sensitivity.
Prior to coupling with maleimide-PEG-grafted lipo-
somes, transferrin was thiolated through incubation with
Traut’s reagent (2-iminothiolane) at a 10:1 2-iminothiola-
ne:protein molar ratio for 1 h at room temperature. Different
Trf-SH to phospholipid molar ratios were then tested in
order to optimise the coupling procedure (Fig. 1).
Fig. 1A shows the effect of Trf-SH:phospholipid molar
ratio on the transferrin density (mg Trf:mmol phospholipid)
at liposomal surface. As can be observed in Fig. 1A, higher
Trf-SH:phospholipid molar ratios resulted in higher liposo-
mal surface densities of Trf. When a 10:1000 Trf-SH:pho-
spholipid molar ratio was used, a density of approximately
200 mg of Trf/mmol phospholipid was achieved. Consider-
ing that one liposome particle with a mean diameter of
150 nm bears approximately 200,000 lipid molecules, each
liposome particle will contain 313 molecules of Trf [19]. A
further increase in the Trf-SH:phospholipid molar ratio
(20:1000) did not improve the amount of transferrin coupled
to the liposomes (data not shown). Therefore, a 10:1000 Trf-
SH:phospholipid molar ratio was used in all subsequent
studies. To clarify whether the thiolated transferrin was
selectively coupled to the maleimide group at the reactive
PEG terminus, additional control experiments were per-
formed. As can be observed in Fig. 1B, incubation of non-
thiolated transferrin (Trf) with maleimide-PEG-grafted
liposomes did not result in a significant association of the
protein to liposomes. However, when Trf-SH was incubated
with liposomes lacking a maleimide reactive group a
significant amount of protein was found to be associated
to the liposomes. These results suggest that Trf-SH has
the ability to associate in a non-specific manner with PEG-
grafted pH-sensitive liposomes.To observe the liposome surface topology and to
investigate whether thiolated transferrin was coupled to
the distal maleimide end of PEG chains or non-specifically
bound to the liposomal lipid bilayer, AFM studies were
performed. AFM is a high-resolution technique that can
image biological or model membranes on solid supports
under aqueous environments [20,21]. It relies on success-
fully immobilising biological entities to a surface on which
they can be distinguished (the surface must have a
roughness that is small compared to the size of the entity)
[22]. For this reason, mica was chosen as a solid support for
our samples. Since we were dealing with soft samples,
imaging was performed in the tapping mode, which is an
intermittent-contact mode of operation used to reduce
lateral and friction forces. Although this imaging mode
has a slightly lower resolution, it has the advantage of
reducing imaging artefacts or possible modifications of the
surface by the tip [23].
Representative AFM images obtained for the different
liposome formulations are shown in Fig. 2.
When (Mal)PEG-Liposomes were deposited on the mica
support, the AFM imaging showed that a large area of the
mica surface, was covered by a flat and smooth lipid
layer, easily distinguished from the rougher mica surface
(Fig. 2A). The height of this lipid layer was 5.6 nm
as determined by cross-sectional analysis, which is in
agreement with previously reported values for lipid
bilayers formed upon adsorption of liposomes to solid
supports [21,24].
In the case of Trf-SH-(Mal)PEG-Liposomes or samples
obtained from the mixture of Trf-SH with PEG-Liposomes
(Fig. 2B and C), besides this smooth lipid bilayer additional
irregular structures were observed. Such structures could
result from transferrin associated to liposomes since they
were not observed in control samples (liposomes lacking Trf,
Fig. 2A). Furthermore, these structures cannot be attributed
to intact liposomes, lipid fragments or aggregates because
these are known to be efficiently removed from the samples
after the washing procedure [25]. A different distribution
pattern of these structures was observed depending on the
formulation. In the case of Trf-SH-(Mal)PEG-Liposomes
they are mainly located on the top of the lipid bilayer while in
the case of the formulation where Trf-SH is mixed with PEG-
Liposomes such structures are located in the form of
aggregates at the mica surface (height of approximately
2.3 nm, for both formulations). Previous studies on the
topology of transferrin molecules on mica surfaces revealed
that transferrin exhibits affinity to mica supports and forms
structures of approximately 2 nm height [26]. These results
corroborate our hypothesis that these structures result from
transferrin associated to liposomes. The different distribution
pattern observed for the two formulations may be explained
by the different location of the transferrin associated to the
liposomes. In the case of Trf-SH-(Mal)PEG-Liposomes, Trf
is mainly covalently linked to the reactive maleimide group
and, therefore, structures were observed predominantly on
Fig. 2. Surface topography analysis of liposomes by atomic force microscopy. Different formulations of liposomes, (A) (Mal)PEG-Liposomes without
transferrin, (B) Trf-SH-(Mal)PEG-Liposomes or (C) Trf-SH mixed with PEG-Liposomes, were deposited on freshly cleaved mica and incubated for 30 min in
Hepes buffer (0.5 mM phospholipid concentration). After the washing procedure, samples were kept in HEPES buffer and introduced as such into the AFM
fluid cell. All imaging was performed using a Digital Instruments Nanoscope IIIa AFM system (Santa Barbara, CA) and a tapping mode fluid cell.
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mixture of Trf-SH with PEG-Liposomes, transferrin was
only adsorbed on the liposome surface (Fig. 2C). Due to the
high affinity of transferrin to the mica surface, it is possible
that for the latter case, upon adsorption and attachment of
liposomes, transferrin had moved from liposome surface to
the mica support.
It is well established that clearance of liposomes from the
circulation and their biodistribution depend on the physico-
chemical properties of the liposomes such as size and surface
charge, among others. Small-sized liposomes (100–200 nm)
show prolonged circulation times in blood because they arenot so easily recognised, as occurs with large vesicles, by the
cells in the RES which are responsible for their removal from
circulation [27,28]. In addition, smaller liposomes show
higher capacity to extravasate into diseased tissues, such as
solid tumours, as compared to larger vesicles [29]. Regarding
the effect of liposomal net charge, recent studies indicate that
positively or negatively charged liposomal surfaces show
increased levels of binding to serum proteins and, conse-
quently, are rapidly removed from circulation [27].
Table 1 illustrates the results obtained for particle size
distribution and surface charge of the different liposome
formulations used in this work.
Fig. 3. Effect of incubation time and lipid concentration on the extent of cell
association of different liposome formulations. Rhodamine-PE labelled
(5 mol% Rh-PE) liposomes (final phospholipid concentration of 100 or
300 mM) were incubated with CEM cells (1!106 cells/well) in RPMI
culture medium for 1 or 2 h at 37 8C. Then, cells were washed twice, re-
suspended in 2 ml of cold PBS and finally analysed for their fluorescence
intensity following the addition of 20 ml of C12E8 (20 mM) in a SPEX
Fluorolog 2 fluorometer (SPEX Industries, Edison, NJ).
Fig. 4. Cell association studies. CEM cells (1!106/well) were incubated
for 30 min at 37 8C in the absence (control) or the presence of an excess of
free Trf (8 mg/well) or with cytochalasin B (25 mg/ml). Cells were further
incubated for 2 h at 37 8C with different liposome formulations (final
phospholipid concentration of 300 mM). Then, cells were washed twice, re-
suspended in 2 ml of cold PBS and finally analysed for their fluorescence
intensity following the addition of 20 ml of C12E8 (20 mM) in a SPEX
Fluorolog 2 fluorometer (SPEX Industries, Edison, NJ).
Table 1
Physicochemical characterisation of different liposome formulations
Formulation Mean
diameter (nm)
Polydispersity
index
z potential
(mV)
PEG-Lip 140 0.13 n.d.
Trf-SHCPEG-Lip 146G1 0.09 n.d
(Mal)PEG-Lip 138G1 0.16 K3.46
Trf-SH-(Mal)PEG-Lip 150G3 0.13 K4.26
Non-thiolated TrfC
(Mal)PEG-Lip
136G3 0.16 n.d.
Mean diameter and polydispersity index were measured by photon
correlation spectroscopy using a Coulter N4 Plus instrument (Coulter
Electronics, Hialeah, FL) and z potential was determined by Doppler
Electrophoretic Light Scattering Analysis using a Coulter DELSA 440
(Coulter Electronics, Hialeah, FL). n.d., non-determined.
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diameter%150 nm and exhibited a homogeneous size
distribution (polydispersity index!0.16). The presence of
transferrin did not significantly affect the final particle size.
With respect to surface charge both (Mal)PEG-Liposomes
and Trf-SH-(Mal)PEG-Liposomes formulations exhibited a
surface charge close to neutrality with values of K3.46 and
K4.26 mV, respectively. Overall, these results show that
the methodology used for the liposome preparation and the
lipid composition selected in this work allowed the
formation of liposomes exhibiting biophysical properties
suitable for intravenous administration.
In vitro studies previously performed suggested that the
transferrin receptor, could be investigated as a possible
mediator of liposome uptake by human T-leukaemia cells
[30]. Therefore, in order to evaluate whether the covalent
attachment of transferrin to (Mal)PEG-Liposomes would
selectively target liposomes to cells in culture, cell
association studies were carried out using two different
human T-leukaemia cell lines (CEM and MOLT-3 cells).
As can be observed in Fig. 3, fluorimetric studies indicate
that an increase both in the incubation time and phospho-
lipid concentration resulted in a higher degree of liposome–
cell association.
Trf-SH-(Mal)PEG-Liposomes (targeted formulation)
showed a 2-fold increase in in vitro cell association as
compared to either Trf-SH mixed with PEG-Liposomes
or to (Mal)PEG-Liposomes (non-targeted formulations)
(Fig. 4).
Competitive inhibition studies indicated that pre-treat-
ment of CEM cells with an excess of free transferrin (at
non-toxic concentrations) resulted in a decrease in the
extent of cell association of the targeted liposomes but had
no effect on the association of the non-targeted formu-
lations. On the other hand, pre-treatment of cells with
cytochalasin B, a drug that is known to block phagocytosis
but not receptor-mediated endocytosis [4,31] had no
significant effect on the extent of cell association of Trf-
SH-(MAL)PEG-Liposomes (Fig. 4). Similar results were
obtained with the MOLT-3 cell line (data not shown).The extent of cell association of the different liposome
formulations with CEM cells was further evaluated by
confocal microscopy (Fig. 5).
As can be observed in Fig. 5, the results were consistent
with those obtained from the fluorimetric studies. Following
incubation of CEM cells with Trf-SH-(Mal)PEG-Liposomes
Fig. 5. Confocal microscopy images of CEM cells incubated with different formulations of Rh-PE labelled liposomes (final phospholipid concentration of
300 mM). Cells (1!106) were incubated with Trf-SH-(Mal)PEG-Liposomes (targeted-liposomes) (A) in the absence or (B) in the presence of inhibitors of
endocytosis composed of a mixture of antymicin A (1 mg/ml), NaF (10 mM) and NaN3 (0.1%) for 1 h at 37 8C. As additional controls, cells were incubated
with (C) (Mal)PEG-Liposomes (liposomes without Trf) or with (D) Trf-SHCPEG-Liposomes (liposomes without (Mal)PEG-DSPE but mixed with Trf-SH).
Following incubation, cells were washed twice with cold PBS, fixed with 4% paraformaldehyde and then washed twice again with cold PBS. Cells were
observed using a Confocal Microcope (Bio-Rad MRC 600, Hercules, CA).
Fig. 6. Viability of CEM cells under different experimental conditions.
Cells (1!106) were incubated with different formulations of Rh-PE
labelled liposomes ((A) Trf-SH-(Mal)PEG-Lip; (B) Trf-SHCPEG-Lip; (C)
(Mal)PEG-Lip, final phospholipid concentration of 300 mM), with (D) free
Trf (8 mg/well) or with (E) a mixture of inhibitors of endocytosis composed
of antymicin A (1 mg/ml), NaF (10 mM) and NaN3 (0.1%), for 2 h at 37 8C.
Cell viability was determined by the MTT assay and expressed as a
percentage of untreated control cells.
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and the cell membrane (Fig. 5A), while for non-targeted
formulations the fluorescence intensity was much lower and
mainly located at the cell surface (Fig. 5C and D).
Furthermore, pre-treatment of the cells with inhibitors of
endocytosis followed by incubation with Trf-SH-(Mal)PEG-
Liposomes resulted in a drastic decrease of fluorescence
intensity, and only traces of puntacted fluorescence were
observed at the cell periphery (Fig. 5B). It should be noted
that cell viability was not affected by the presence of
inhibitors of endocytosis, as assessed by the tetrazolium dye
assay of Mosmann (MTT assay) (Fig. 6) [32]. Therefore, the
inhibitory effect on cell association observed under this
condition cannot be attributed to any cytotoxic effect of the
drugs.
Fluorimetric studies and confocal microscopy analysis
demonstrated that association of targeted liposomes to
leukaemia cells occurs at a significantly larger extent than
non-targeted formulations. Notably, (Mal)PEG-Liposomes
(liposomes without transferrin) and the mixture of Trf-SH
with PEG-Liposomes, exhibited a similar low extent of cell
association suggesting that in the later formulation,
transferrin is not available to bind to its receptor. These
data support our previous hypothesis that in the case of
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rin may be non-specifically adsorbed to the liposome
surface. Most likely, protein molecules become intercalated
between PEG chains, thus preventing the interaction
between transferrin and its receptor. In contrast, for Trf-
SH-(Mal)PEG-Liposomes, transferrin is indeed covalently
coupled to the terminal end of PEG-grafted liposomes thus
becoming easily accessible for receptor binding.
In conclusion, this work demonstrated that the use of a
targeting ligand that binds to receptors which undergo
internalisation combined with the ability of the developed
formulation to promote pH-triggered cytoplasmic delivery
of loaded material leads to a promising strategy for in vivo
targeting of therapeutic molecules to leukaemia cells.Acknowledgements
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